Zymeworks becomes the latest mesothelin dropout
The group cans ZW171 after “on-target, off-tumour toxicity”.
Roche perseveres with FAP
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
The group cans ZW171 after “on-target, off-tumour toxicity”.
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
